A complex case of piperacillin-tazobactam resistant Elizabethkingia anophelis neonatal meningitis: the challenge of treatment and literature review Authors: Yixiang Wu, Sitian Ke, Lizhong Du, Zhongyue Li Published: 2026 ABSTRACT AbstractBackgroundElizabethkingia anophelis is an emerging multidrug-resistant pathogen associated with severe neonatal infections and high mortality. Due to its intrinsic resistance to multiple antibiotics, including β-lactams, optimal antimicrobial therapy remains challenging. We report a rare case of neonatal meningitis complicated by brain abscess caused by piperacillin-tazobactam–resistant Elizabethkingia anophelis.Case presentationA full-term neonate presented with fever and poor responsiveness on day 15 after birth. Initial empirical antibiotic therapy was ineffective. Blood culture confirmed Elizabethkingia anophelis with resistance to piperacillin-tazobactam. Based on antimicrobial susceptibility testing, the treatment regimen was adjusted to levofloxacin combined with vancomycin. The patient showed marked clinical improvement, with normalization of temperature, negative blood cultures, and gradual resolution of the brain abscess. No significant adverse effects were observed during treatment.ConclusionThis case highlights the challenge of individualized antimicrobial selection in piperacillin-tazobactam-resistant neonatal Elizabethkingia meningitis. Early pathogen identification and timely optimization of antimicrobial therapy, including the judicious use of fluoroquinolones, may be critical for improving clinical outcomes.Keywords: Elizabethkingia anophelis, Nneonate, Meningitis, Brain abscess, Antimicrobial resistance Background Neonates are vulnerable to severe bacterial infections caused by both Gram-positive and Gram-negative organisms, with presentations ranging from early- to late-onset sepsis. Multidrug-resistant Gram-negative infections pose additional therapeutic challenges because treatment options are often limited. This heightened susceptibility is attributed to factors such as premature of innate immunity, preterm birth, extended hospitalization, and the necessity for various invasive procedures, including intravascular catheterization. In addition to hospital-acquired infections, recent attention has increasingly been directed towards community-acquired late-onset sepsis, which is caused by certain multidrug-resistant bacteria [1]. Elizabethkingia anophelis is an opportunistic pathogenic bacterium extensively distributed across various natural environments, such as soil, plants, freshwater, as well as healthcare settings [2]. This bacterium demonstrates multidrug resistance, including resistance to most β-lactams, β-lactam/β-lactamase inhibitor combinations, carbapenems, and aminoglycosides. The clinical manifestations observed in neonatal patients following infection are notably severe, frequently presenting as septicemia, meningitis, and other critical conditions, accompanied by high mortality and morbidities. Antimicrobial treatment of neonatal Elizabethkingia anophelis infection is challenging because this pathogen may show resistance to antibiotics commonly used as empirical therapy in neonatal intensive care units, including third-generation cephalosporins, penicillin-class agents, and vancomycin. Although piperacillin-tazobactam-containing regimens have been reported to be successful in a small number of neonatal cases [3–6], susceptibility patterns may vary between isolates. In the present case, the isolate was resistant to piperacillin-tazobactam but susceptible to levofloxacin. This created a therapeutic challenge because neonatal evidence regarding the appropriate dose, treatment duration, and safety of levofloxacin remains limited [7]. Therefore, this case provides additional clinical experience regarding individualized, susceptibility-guided antimicrobial selection for this rare neonatal infection. In this report, we describe the clinical course of a community-acquired neonatal Elizabethkingia anophelis purulent meningitis case complicated by brain abscess formation, characterized by piperacillin-tazobactam resistance and levofloxacin susceptibility. We further reviewed previously reported neonatal cases to summarize antimicrobial susceptibility profiles, treatment regimens, and clinical outcomes. Case The neonate was delivered by cesarean section at 38 weeks and 2 days of gestation at another hospital because of oligohydramnios, with a birth weight of 2600 g. There was no history of birth asphyxia or resuscitation. Apart from oligohydramnios, no abnormalities of the fetal membranes, umbilical cord, or placenta were reported. The infant remained well during rooming-in with his mother and after discharge home. On day 15 of life, he developed a low-grade fever at home, accompanied by crying, irritability, and restlessness.Two days subsequently, the infant was brought to the outpatient department of our hospital, where the low-grade fever persisted alongside somnolence and mild irritability. Physical examination revealed increased tension in the anterior fontanelle, but no apparent lateralizing neurological signs were observed.Empirical antibiotic therapy with cefotaxime was promptly initiated to address a suspected infection, and a lumbar puncture was performed. Routine cerebrospinal fluid (CSF) analysis demonstrated 580 cells/mm3.On the same day, after the preliminary microbiological report of the CSF culture indicated Gram-negative bacilli, cefotaxime was replaced by meropenem at a meningitis dose of 40 mg/kg every 8 h. Since admission, the infant had intermittent fever, with temperatures ranging from 37.9 °C to 39.2 °C. Serum C-reactive protein (CRP) increased from 66.1 mg/L on admission to 127.6 mg/L on hospital day 2, with a local reference cut-off value of 6 mg/L. On hospital day 2, approximately 4 days after symptom onset, both blood and CSF cultures were reported positive for Elizabethkingia anophelis, while antimicrobial susceptibility results were still pending.Based on a review of the literature, vancomycin was added for antibiotic management. By the third day of hospitalization, the infant’s fever persisted, with body temperature ranging from 37.7 °C to 38.2 °C, accompanied by irritability and a bulging fontanelle. A repeat lumbar puncture revealed an elevated white blood cell count of 840 in the cerebrospinal fluid. At this juncture, antimicrobial susceptibility testing showed that the isolate was resistant to ceftriaxone, gentamicin, meropenem, and piperacillin-tazobactam, but susceptible to ciprofloxacin, levofloxacin, and trimethoprim-sulfamethoxazole. Based on the susceptibility profile, central nervous system infection, and clinical condition, levofloxacin was added.Consequently, levofloxacin was administered at the pediatric standard dosage of 20 mg/kg/day, divided by every 12 h, for infection control. On hospital day 3, corresponding to the fourth day of fever, cranial MRI showed abnormal patchy T1 hyperintense signals in the bilateral basal ganglia, brainstem, and lateral ventricular regions (Fig. 1), indicating early intracranial abnormalities. No definite brain abscess was identified at that time. On the fourth day of hospitalization, the child exhibited new symptoms, notably an upward rolling of both eyes with a fixed gaze lasting several seconds, followed by spontaneous remission. Despite these developments, the child’s body temperature showed gradual improvement. After 48 h of administering levofloxacin, a repeat cerebrospinal fluid analysis indicated a white blood cell count of 620, signifying improvement compared to previous results, thereby justifying the continuation of the treatment (Table 1). On the seventh day of hospitalization, a cranial ultrasound revealed multiple anechoic areas within the brain parenchyma and the presence of an abscess (Fig. 2).The lesions were small and multifocal; however, precise measurements were not provided in the original ultrasound report. In addition to exhibiting dull eyes and slightly elevated muscle tone, the child did not display any other neurological signs or symptoms. Although the infant’s feeding improved, antimicrobial therapy was not de-escalated because cranial ultrasound findings suggested brain abscess formation, indicating severe central nervous system infection. An additional vancomycin disk diffusion test performed by our laboratory showed an inhibition zone; however, this result was interpreted cautiously because standardized interpretation of vancomycin susceptibility for Elizabethkingia species remains uncertain. Given the severity of infection, the observed in vitro inhibition, and previous reports describing vancomycin-containing combination regimens, vancomycin was continued as adjunctive combination therapy with levofloxacin under close clinical monitoring.On the tenth day of hospitalization, a follow-up cranial magnetic resonance imaging (MRI) scan revealed no evidence of a brain abscess (Fig. 1), with a marked reduction in high signal intensity compared to previous imaging. Subsequent cranial ultrasound confirmed the resolution of the brain abscess. The patient received antimicrobial therapy for a total of 37 days. After levofloxacin was added on hospital day 3, vancomycin combined with levofloxacin was continued for 34 days. The treatment duration was determined by the severity of meningitis complicated by brain abscess formation and was continued until clinical improvement and normalization of cerebrospinal fluid findings were achieved. The patient was then discharged in stable clinical condition on hospital day 38.Throughout the treatment period, the patient’s hepatic and renal functions remained stable, with urine output, blood urea nitrogen, and serum creatinine levels all within normal limits. Post-discharge, the patient was subject to long-term follow-up, including regular X-ray or MRI evaluations of bones and joints, which did not reveal any adverse musculoskeletal effects. Periodic brain MRI assessments showed no abnormal signals, and the patient’s growth and development were in line with peers of the same age at the 1 year following discharge.The chronological clinical course, antimicrobial adjustment, and follow-up status are summarized in Table 2. This study is not a clinical trial. Clinical trial number: not applicable. Serial brain magnetic resonance imaging (MRI) findings. A, D T1-weighted MRI obtained on hospital day 3 demonstrates patchy hyperintense lesions (arrows) involving the bilateral posterior limbs of the internal capsule, brainstem, and cerebellum. B, E Follow-up MRI on hospital day 9 shows marked reduction of the previously noted hyperintensities. C, F Follow-up MRI on hospital day 34 demonstrates further resolution of the lesions Table 1Characteristics of the patient with Elizabethkingia anophelis infectionCharacteristicDay1Day3Day5Day10Day17Day24Day31Day38Cerebrospinal fluidWBC count (cells/mm3)5808406201401101709515Glucose (mmol/l)0.170.360.231.361.441.722.241.78Proteins (mg/L)2113.63419.32767.31455.11342.61253.812631011.6Bacterial cultureGram-negativeElizabethk-ingiaanophelisElizabethk-ingiaanophelisnegativenegativenegativenegativenegativeBloodWBC count (cells/mm3)10.714.39.31110.47.47.26.3Neutrophils (%)68.150.636.233.522.828.621.436CRP (mg/dL)66.192.5150.60.3<0.2<0.21.2Bacterial cultureNAElizabethk-ingiaanophelisElizabethk-ingiaanophelisnegativenegativenegativenegativenegativeAbbreviations: NA not available Characteristics of the patient with Elizabethkingia anophelis infection Gram -negative Elizabethk-ingia anophelis Elizabethk-ingia anophelis Elizabethk-ingia anophelis Elizabethk-ingia anophelis Abbreviations: NA not available Cranial ultrasonography findings. Cranial ultrasound performed on hospital day 7 demonstrates multiple anechoic abscesses within the brain parenchyma at the junction of the frontal and parietal lobes (arrows) Table 2Summary timeline of the clinical courseTime pointClinical course and managementBirth and early postnatal periodThe neonate was delivered by cesarean section at 38 + 2 weeks for oligohydramnios, with a birth weight of 2600 g and no birth asphyxia or resuscitation. The early postnatal course was uneventful during rooming-in and after discharge home.Day 15 of lifeLow-grade fever, crying, irritability, and restlessness developed at home.Hospital day 1(Day 17 of life)The patient was admitted with suspected neonatal meningitis. Cefotaxime was initially started. After cerebrospinal fluid examination reported Gram-negative bacilli, antimicrobial therapy was escalated to meropenem on the same day.Hospital day 2Elizabethkingia anophelis was identified, while antimicrobial susceptibility results were still pending. Empirical treatment with meropenem plus vancomycin was continued.Hospital day 3Antimicrobial susceptibility testing showed resistance to piperacillin-tazobactam. Levofloxacin was added according to the susceptibility profile and clinical condition.Hospital day 7Cranial ultrasound showed multiple intraparenchymal anechoic lesions, suggesting brain abscess formation.Subsequent courseThe patient’s clinical condition gradually improved. Repeated blood and cerebrospinal fluid cultures were negative, and antimicrobial therapy was continued to complete the planned course.Follow-upAt 1-year follow-up, growth and developmental milestones were appropriate for age. Serial brain MRI showed no abnormal signals, and no apparent neurological sequelae or musculoskeletal adverse effects were observed. Summary timeline of the clinical course Hospital day 1 (Day 17 of life) Discussion Neonates are highly vulnerable to severe infections due to their underdeveloped immune systems and limited maternal antibodies, increasing their risk of neonatal septicemia [8, 9], which can be early-onset (from prenatal or intrapartum infections) or late-onset (acquired post-birth). Hospital factors like extended stays and invasive procedures heighten infection risk. The immature blood-brain barrier in neonates allows pathogens to spread to the central nervous system, leading to serious complications [10]. Elizabethkingia anophelis is a Gram-negative bacillus that can be found in environmental reservoirs such as water and soil and has emerged as an opportunistic pathogen in vulnerable hosts, including neonates [11, 12]. In this case, the infant developed symptoms on day 15 of life, had no previous hospitalization, and had remained well at home after birth, suggesting a community-acquired infection rather than a hospital-acquired infection. However, no definite source of infection or transmission route was identified. A detailed review of the exposure history revealed that the infant’s grandfather had been hospitalized in an intensive care unit before the onset of the infant’s symptoms. Therefore, colonization of a close household contact with subsequent transmission through close contact could not be excluded. Nevertheless, this remains speculative because cultures from household contacts or the home environment were not performed.Utilizing the keywords “Elizabethkingia Anophelis,” “Elizabethkingia,” “infant,” “neonate,” and “neonatal,” we conducted a comprehensive literature search across databases including PubMed, Embase, Web of Science, CNKI, VIP, Wanfang and the Chinese Medical Journal Full-text Database, covering publications up to December 2024. Following the removal of duplicate entries, 92 articles were retained. After excluding repeated reports, cases attributed to other Elizabethkingia strains, and infections occurring in different age groups (totaling 78 articles), we ultimately included 14 articles published in English [3–6, 12−21]. Incorporating the present case, the cumulative number of neonatal patients reached 68. Within the reviewed literature, 80.8% of cases were identified as nosocomial infections, whereas 11.7% were classified as community-acquired infections (Table 3). Table 3Characteristics of pediatric patients with Elizabethkingia anophelis infectionsNumberCases of patientsGestational age(weeks)Age(days)/sexClinical diagnosisSource of infectionSpecimen typeResistance profileSusceptible antibioticsAntibiotic treatmentOutcome1 [12]1NA8/NAMeningitisCABlood, CSFTMP/SMZ, fluoroquinolones, aminoglycosides, and carbapenemsMinocyclineTMP/SMZ plus ciprofloxacin; rifampicin (22 days)Survival with neurologic sequelae2 [13]1274/FPneumoniaHABloodNAVancomycin, TMP/SMZ, rifampicin, fluoroquinolonesVancomycin plus rifampicin(2 weeks)Survival3 [14]9NANA/NANAHABloodVancomycin,piperacillin–tazobactamTMP/SMZ, fluoroquinolones, minocyclineLevofloxacin, TMP/SMZ1 Death/ 8 Survival4 [15]38345/52.6%MSepsis/meningitisHABlood,CSFCefoperazone–sulbactam, TMP/SMZ, and fluoroquinolonesMinocycline, levofloxacinCefoperazone–sulbactam plus amikacin23.7% Death5 [16]1NA5/FMeningitisCACSFPenicillins, cephalosporins, and carbapenemsPiperacillin, aminoglycosides, TMP/SMZ, fluoroquinolones, linezolidAmpicillin plus gentamicinDeath6 [3]13622/MMeningitisCACSFAminoglycosides, fluoroquinolones, cephalosporins, and carbapenemsmPiperacillin–tazobactamVancomycin plus piperacillin–tazobactam (4 weeks)Survival with hydrocephalus7 [3]139 + 318/FMeningitisCACSFAminoglycosides, fluoroquinolones, cephalosporins, and carbapenemsPiperacillin–tazobactamVancomycin plus piperacillin–tazobactam (6 weeks)Survival with VP shunt8 [4]14121/MSepsis/meningitisCABlood, CSFβ-lactams, aminoglycosides, tetracyclines, and chloramphenicolPiperacillin, cefoperazone–sulbactam, fluoroquinolones, TMP/SMZ, vancomycinVancomycin plus piperacillinSurvival9 [4]130NA/FSepsis/meningitisIUIBlood, CSFβ-lactams, aminoglycosides, tetracyclines, and chloramphenicolPiperacillin, cefoperazone-sulbactam, fluoroquinolones, TMP/SMZVancomycin plus piperacillin–tazobactam and rifampicinSurvival with IVH10 [17]1380/FmeningitisHABlood, CSFCephalosporins, carbapenems, and aminoglycosidesCiprofloxacin, cefoperazone-sulbactam, vancomycinVancomycin and rifampicinSurvival11 [17]13721/MmeningitisHACSFCephalosporins, carbapenems, and aminoglycosidesCiprofloxacin, cefoperazone-sulbactam, vancomycinVancomycin, piperacillin, and rifampicin (≥ 2 weeks)Survival12 [18]1367/FSepsis/meningitisCABloodCeftriaxone, vancomycinTMP/SMZ, ciprofloxacinCiprofloxacin plus vancomycin (28 days)Survival with neurologic deficits13 [18]1NA0/MSepsisNABloodCeftriaxone, vancomycinTMP/SMZ, ciprofloxacinAmpicillin plus gentamicin(5 days)Death14 [18]1NA0/MSepsisNABloodCeftriaxone, vancomycinTMP/SMZ, ciprofloxacinImipenem(35days)Survival15 [18]1NA0/FSepsisNABloodCeftriaxone, vancomycinCiprofloxacinAmpicillin plus gentamicin(25days)Death16 [5]1NA11/MPneumonia/sepsisNABlood, CSFCarbapenems, cephalosporins, and aminoglycosidesCo-trimoxazole,Ciprofloxacin, LevofloxacinVancomycin, piperacillin–tazobactam, and ciprofloxacin (25 days)Survival17 [19]13612/MMeningitisCABlood, CSFCephalosporins, carbapenems, aztreonam, and aminoglycosideslevofloxacin, TMP/SMZ,tetracyclinesTMP/SMZ, ciprofloxacin, and rifampicin(8 weeks)Survival with VP shunt18 [20]12911/MMeningitisHABlood, CSFAminoglycosides, cephalosporins, and carbapenemsTMP/SMXVancomycin, rifampin,ciprofloxacin, TMP/SMZ (21 days)Survival with VP shunt19 [6]1NA12/MSepsisHABlood, CSFFluoroquinolones,cephalosporins,Minocycline,piperacillin-tazobactamMinocycline plus piperacillin-tazobactam(34days)Survival20 [6]1NA7/MMeningitisHABlood, CSFFluoroquinolones,cephalosporins,Minocycline,Piperacillin-tazobactam,vancomycinMinocycline, piperacillin–tazobactam, and vancomycin (16 days)Survival21 [6]1NA19/FMeningitisHABlood, CSFFluoroquinolones,cephalosporins,Minocycline, Piperacillin-tazobactam,vancomycinMinocycline, piperacillin–tazobactam, and vancomycin (11 days)Survival22 [21]1NA2/FSepsisHABloodcephalosporins, carbapenems, and aminoglycosidesTMP/SMZ, fluoroquinolones,piperacillin–tazobactamAmpicillin, gentamicinNAAbbreviations: CSF cerebrospinal fluid, VP ventriculoperitoneal shunt, HCM hypertrophic cardiomyopathy, IDM infant of a diabetic mother, CA community-acquired, HA hospital-acquired, NA not available, IUI intrauterine infection, TMP/SMZ trimethoprim-sulfamethoxazole, TMP/SMX trimethoprim-sulfamethoxazole, IVH intraventricular hemorrhage, F female, M male Characteristics of pediatric patients with Elizabethkingia anophelis infections Vancomycin plus rifampicin (2 weeks) Vancomycin, piperacillin–tazobactam Sepsis/ meningitis Blood, CSF Sepsis/ meningitis Sepsis/ meningitis Sepsis/ meningitis Ampicillin plus gentamicin (5 days) Pneumonia/ sepsis Co-trimoxazole, Ciprofloxacin, Levofloxacin levofloxacin, TMP/SMZ, tetracyclines TMP/SMZ, ciprofloxacin, and rifampicin (8 weeks) Vancomycin, rifampin, ciprofloxacin, TMP/SMZ (21 days) Fluoroquinolones, cephalosporins, Minocycline, piperacillin-tazobactam Minocycline plus piperacillin-tazobactam (34days) Fluoroquinolones, cephalosporins, Minocycline, Piperacillin-tazobactam, vancomycin Fluoroquinolones, cephalosporins, Minocycline, Piperacillin-tazobactam, vancomycin TMP/SMZ, fluoroquinolones, piperacillin–tazobactam Abbreviations: CSF cerebrospinal fluid, VP ventriculoperitoneal shunt, HCM hypertrophic cardiomyopathy, IDM infant of a diabetic mother, CA community-acquired, HA hospital-acquired, NA not available, IUI intrauterine infection, TMP/SMZ trimethoprim-sulfamethoxazole, TMP/SMX trimethoprim-sulfamethoxazole, IVH intraventricular hemorrhage, F female, M male The current incidence of neonatal infections caused by Elizabethkingia is relatively low. Nevertheless, the resultant neonatal purulent meningitis in Homo sapiens is associated with high mortality rates and significant long-term complications, such as hydrocephalus, hearing loss, and developmental delays [22]. The extant literature suggests that Elizabethkingia exhibits resistance to β-lactams, broad-spectrum cephalosporins, carbapenems, and gentamicin, while remaining susceptible to vancomycin, co-trimoxazole, rifampicin, and ciprofloxacin, with intermediate susceptibility to piperacillin. In the present case, multiple cerebrospinal fluid and blood cultures from the infant revealed that the isolated strain was resistant to β-lactam antibiotics, extended-spectrum cephalosporins, carbapenems, aztreonam, aminoglycosides, and tetracyclines, but susceptible to chloramphenicol, levofloxacin, and co-trimoxazole. Although the isolate was susceptible to chloramphenicol in vitro, it was not selected because of neonatal safety concerns, including gray baby syndrome and hematologic toxicity, and because therapeutic drug monitoring was not available [23, 24]. Levofloxacin was therefore selected as an individualized, susceptibility-guided option with close clinical follow-up.Furthermore, the laboratory department of our hospital performed supplementary disk diffusion assays on the dissociation strain, consistently demonstrating sensitivity to vancomycin. Although disk diffusion is not the preferred method for assessing antibiotic susceptibility, the Vitek system is unable to evaluate the sensitivity of non-fermenting Gram-negative bacilli to vancomycin. In previously published case series, neonates with Elizabethkingia infections were successfully treated by physicians using a combination of piperacillin and vancomycin [25]. Nonetheless, all dissociation strains we cultured exhibited resistance to both piperacillin and piperacillin-tazobactam. Levofloxacin, a fluoroquinolone antibiotic, demonstrates significant bactericidal efficacy both in vitro and in vivo. It is characterized by excellent penetration of the blood-brain barrier and the attainment of high concentrations in cerebrospinal fluid, rendering it a potentially effective treatment for meningitis.Concerns regarding fluoroquinolone use in children were initially based on juvenile animal studies showing cartilage toxicity [26]. However, subsequent pediatric clinical studies have not demonstrated a high risk of irreversible musculoskeletal injury, and reported musculoskeletal adverse events are generally uncommon or reversible. Therefore, current practice does not regard fluoroquinolones as absolutely contraindicated in children, but recommends restricted and individualized use when safer effective alternatives are unavailable and the expected benefits outweigh potential risks [27–29]. In neonates, however, evidence remains particularly limited and is largely confined to case reports or small case series; therefore, levofloxacin should be used cautiously with close short- and long-term safety monitoring [30]. In this particular case, informed by drug sensitivity results, we implemented a combination therapy comprising levofloxacin and vancomycin to address the infection. Vancomycin was administered at dosages appropriate for meningitis, while levofloxacin was administered at standard pediatric dosages due to the absence of specific guidelines for its use in neonates. Specifically, intravenous levofloxacin was administered at a dosage of 10 mg/kg every 12 h. The accelerated renal clearance of levofloxacin in infants and young children, nearly twice the rate observed in adult Homo sapiens, necessitated the 12-hour dosing interval. Given the persistent and severe nature of the intracranial infection in this patient, coupled with the anticipated larger volume of distribution in neonates, a higher dosage was considered necessary. However, levofloxacin can achieve high concentrations in cerebrospinal fluid, and recent studies have shown that the systemic clearance of ciprofloxacin in infants under 3 months of age is lower than in Homo sapiens and older children, hence a reduced dosage is recommended [31]. Therefore, we determined the optimum dose regimen of levofloxacin for intracranial infection in critically ill full-term and premature delivery neonates: intravenous administration of levofloxacin at 10 mg/kg per dose, every 12 h. Through this treatment, the infant’s body temperature rapidly stabilized, and the intracranial infection was effectively controlled. For typical intracranial infections, such as those caused by Gram-negative enteric bacteria including Pseudomonas and Escherichia coli, a standard 21-day antimicrobial treatment regimen is generally required. However, in cases of meningitis in infants where there is a delayed clinical response to initial treatment or the development of complications such as brain abscess, cerebral ventriculitis, or cerebral infarction, an extended treatment duration is advised [32]. A review of 67 cases of neonatal Elizabethkingia anophelis infection indicated that the mean treatment duration was 26 days. Experts recommend performing a repeat lumbar puncture in infants who do not exhibit clinical improvement within 24 to 48 h of initiating antibiotic therapy. Conversely, for infants who show rapid clinical improvement following the commencement of antibiotics and achieve successful resolution of the infection, a repeat lumbar puncture is deemed unnecessary [33]. In this case, the child underwent a cranial ultrasound on the seventh day of illness, which revealed the presence of a brain abscess. Over the course of the disease, the child underwent lumbar puncture on eight occasions. During the fourth lumbar puncture, the cerebrospinal fluid culture first tested negative. Given that the bacterial genus responsible for the infection was relatively rare and exhibited multidrug resistance, and considering the complications that arose during treatment, the anti-infective regimen was extended until the cerebrospinal fluid cell count normalized upon re-examination. This resulted in a total effective treatment duration of 34 days. Following successful treatment, a follow-up cranial MRI conducted the day after the brain abscess was detected indicated resolution of the abscess and improvement in hyperintensity compared to previous findings. Neonatal survivors of purulent meningitis exhibit an elevated risk for enduring neurological disorders. A prospective cohort study, which monitored 1,717 individuals who survived neonatal meningitis up to the age of five, revealed that these children were ten times more likely to develop moderate to severe disabilities compared to their counterparts who had not experienced meningitis [34]. Furthermore, a recent advisory from the U.S. Food and Drug Administration highlighted that fluoroquinolone antibiotics could induce serious and potentially irreversible adverse effects on tendons, joints, muscles, nerves, and the central nervous system. Consequently, although levofloxacin is generally well-tolerated in both pediatric and adult populations, its safety profile in neonatal patients, particularly concerning short- and long-term outcomes, remains inadequately defined and warrants careful consideration.From the time of discharge to the present (at one year of age), the child’s growth and developmental parameters, including height (80 cm) and weight (11.5 kg), have been systematically monitored. Assessments of both gross and fine motor skills indicate no significant delays when compared to age-matched peers. Follow-up cranial MRI scans have not identified any abnormalities associated with parazacco spilurus subsp. spilurus, and no adverse musculoskeletal responses have been observed. Ongoing monitoring will be sustained. This study has several limitations. First, as a single-case report, our findings should be interpreted as clinical experience rather than definitive evidence for the efficacy of levofloxacin. Although the isolate in our case was resistant to piperacillin-tazobactam and levofloxacin was selected according to the antimicrobial susceptibility profile and clinical condition, the favorable outcome cannot prove that levofloxacin is superior to other potential regimens or should be routinely used in neonates with Elizabethkingia anophelis infection. Second, the optimal use of levofloxacin in neonatal meningitis remains uncertain. Data on neonatal dosage, treatment duration, cerebrospinal fluid penetration, pharmacokinetics, and long-term safety are limited. Therefore, the dosage experience described in this case may provide a useful reference, but it requires cautious interpretation and further validation. Third, the patient’s prognosis was assessed based on the available follow-up period, and longer-term neurodevelopmental follow-up is needed because neonatal meningitis itself may be associated with delayed neurological sequelae. Fourth, although we reviewed the available literature up to the end of 2024, most reported neonatal cases were case reports or small case series with heterogeneous clinical characteristics, susceptibility results, antimicrobial regimens, and outcome reporting. Incomplete reporting of antibiotic dosage and treatment duration also limited direct comparison between piperacillin-containing regimens, fluoroquinolone-based therapy, and other treatment strategies. Further multicenter data and accumulated clinical experience are required to define the optimal antimicrobial approach for piperacillin-tazobactam resistant E. anophelis neonatal meningitis. Conclusion Neonatal purulent meningitis represents a critical medical condition necessitating heightened vigilance, prompt diagnosis, and swift therapeutic intervention. The multidrug-resistant bacterium Elizabethkingia anophelis is implicated in neonatal septicemia and meningitis, conditions that are linked to elevated rates of complications and mortality, thereby presenting substantial therapeutic challenges. Although Piperacillin-tazobactam sensitive cases have been reported in majority of literatures, and Piperacillin-tazobactam resistant Levofloxin-sensitive condition should be emphasized.Conducting a timely lumbar puncture to obtain cerebrospinal fluid and neuroimaging follow-up are essential for achieving a definitive diagnosis, identifying the causative pathogen, and optimizing antimicrobial treatment strategies. Acknowledgements Not applicable. Abbreviations Late-onset sepsis Neonatal intensive care unit Cerebrospinal fluid C-reactive protein White blood cell Magnetic resonance imaging Early-onset sepsis Ventriculoperitoneal Hypertrophic cardiomyopathy Infant of a diabetic mother Community-acquired Hospital-acquired Not available Intrauterine infection Trimethoprim-sulfamethoxazole Trimethoprim-sulfamethoxazole Tntraventricular hemorrhage Female Male Authors’ contributions Yixiang Wu designed the study. Sitian Ke collected clinical data. Yixiang Wu and Sitian Ke performed the literature review. Lizhong Du and Zhongyue Li had critical revision for important intellectual content. Yixiang Wu drafted the manuscript. All authors read and approved the final manuscript. Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Data availability All data generated or analyzed during this study are included in this published article. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of the Fourth Affiliated Hospital of School of Medicine. Written informed consent to participate was obtained from the patient’s parents. Consent for publication Written informed consent for publication of this case report and any accompanying images was obtained from the patient’s parents. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this published article.